학술논문
Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression
Document Type
article
Author
Jamie Zagozewski; Stephanie Borlase; Brent J. Guppy; Ludivine Coudière-Morrison; Ghazaleh M. Shahriary; Victor Gordon; Lisa Liang; Stephen Cheng; Christopher J. Porter; Rhonda Kelley; Cynthia Hawkins; Jennifer A. Chan; Yan Liang; Jingjing Gong; Carolina Nör; Olivier Saulnier; Robert J. Wechsler-Reya; Vijay Ramaswamy; Tamra E. Werbowetski-Ogilvie
Source
Communications Biology, Vol 5, Iss 1, Pp 1-17 (2022)
Subject
Language
English
ISSN
2399-3642
Abstract
RNA sequencing of MEK inhibitor (selumetinib)-treated tumors reveals an upregulation of the JAK/STAT3 pathway, with combinatorial therapeutic strategies of JAK/STAT3 inhibitors and selumetinib investigated for the SHH subgroup of medulloblastoma.